Prenetics Launches ColoClear, a Non-Invasive Stool DNA Test to Detect Early Signs of Colorectal Cancer in Hong Kong
- Highly sensitive ColoClear test offers convenient screening method that can be completed with simple stool sample at-home, providing an easy alternative to Colonoscopy - Test sensitivity of 96% in colorectal cancer and 64% in advanced adenoma detection in clinical studies - ColoClear is the only cancer screening test approved by the National Medical Products Administration (NMPA) HONG KONG, June 9, 2022 /PRNewswire/ --Prenetics Group Limited (Nasdaq: PRE), a global leader in genomic and diagnostic testing, has introduced a novel, non-invasive, at-home screening test - ColoClear by Circle (Co...
Source: singaporestar.com
